ALK and non-small cell lung carcinoma: Rearrangements of ALK have been observed in almost 10% of NSCLC patients (Rosas et al., 2019), prompting researchers to conduct studies using ALK tyrosine kinase inhibitors as a novel treatment for lung cancer (Cicin et al., 2022).